investor meet highlight guidanc conserv mitral
tricuspid delay compel
decemb edward held annual investor meet new york citi edward
outlin near- long-term growth driver across busi segment specif
focu product clinic data expans tavr meaning near-
term growth driver tmtt meaning long-term driver manag also
provid full year guidanc larg line street estim
head event
overal continu believ edward well posit deliv upsid
expect support multipl tailwind tavr deliv double-digit top-lin
sale sever year support strong expans pipelin
tavr expect tavr main focu year investor meet
manag highlight underli growth larg due expand low-
risk label overwhelmingli posit protect data outlin catalyst believ
help sustain double-digit tavr growth sever year come manag
assum tavr busi grow rang line market growth
said edward assum growth front-half load normal growth
second half assum low doubl digit prudent like conserv
estim view sever unknown around abil sustain recent
momentum howev market edward specif number catalyst
believ could keep growth expect longer
bolster compani growth initi larg under-penetrated aortic stenosi
opportun manag continu expect grow billion treatment
market impli annual compound-annual-growth-rate next five year
opportun expand market addit popul moder
asymptomat initi may take time run cours
clearli point multi-year double-digit growth stori potenti much larger tam
time
run notabl catalyst sustain tavr growth move
return equiti ttm
edward global leader treatment advanc cardiovascular diseas busi divid three
differ segment transcathet heart valv surgic heart valv critic care
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
near-term catalyst tailwind
expand low-risk label unit state second third quarter tavr growth acceler
respect first quarter heel posit protect data present march
sapien expand indic treat low-risk patient august low-risk approv secur continu
believ convers shift risk group appropri tavr improv access
treatment ultim open approxim sever patient inclus risk categori
unit state less patient treat estim expect tavr market
sustain multipl year midteen better domest market growth believ expand low-risk label
provid strong tailwind growth model growth tavr sale
sapien ultra sapien ultra launch nearli month ago product slower-than-expect
ramp given seemingli poor physician feedback redesign deliveri system result manag
rework ultra valv deploy origin sapien command deliveri system solut physician
much familiar comfort relaunch ultra valv plu command deliveri system
europ unit state today manag highlight posit feedback new old deliveri system
continu believ ultra taller skirt help improv real-world result decreas paravalvular leak
sum somewhat slow start ultra still expect make major tavr sale
expect support increas util also solidifi edward leadership rapidli grow
acceler tavr market allow primari beneficiari market growth
expans within europ manag note recent growth larg driven countri
rel lower tavr penetr rate countri like itali ireland spain less half tavr
util level countri like germani switzerland leav ampl room demand next sever
year benefit new product expand indic end edward receiv ce mark approv
indic includ low-risk novemb provid tailwind growth use
approv chang guidelin secur reimburs european countri throughout year tavr
growth meaning inflect acceler low-risk approv expect benefit come gradual
europ given need guideline/reimburs chang individu countri lastli compani
ramp launch intern market believ help fend competit
pressur price share posit edward leader increasingli competit intern market
 center expans june center medicar medicaid servic publish updat
nation coverag determin ncd tavr center requir slightli lower burden requir
becom certifi tavr center result manag expect number center unit state
increas approxim though contribut new center may ramp slowli
take time establish proper care pathway train tavr team either way addit center across
unit state support increas throughput improv patient access tavr provid broad tailwind
growth beyond
long-term catalyst tailwind
continu expans edward recent expand includ low-risk sever patient
manag alreadi execut initi expans new popul like sever asymptomat
potenti moder symptomat asboth could meaning expand tavr opportun
though admittedli remain long-term goal asymptomat market earli tavr trial greater
enrol expect complet enrol difficult gaug meaning data
readout remain encourag potenti market opportun support overwhelmingli
posit tavr result protect trial poor clinic outcom untreat sever asymptomat patient
exampl recent american heart associ aha scientif meet data present
recoveri randomize-control trial show sever asymptomat patient treat surgic valv
replac saw significantli lower mortal rate compar patient delay treatment vs
size asymptomat sever preval popul patient year old
moder asymptomat front manag still earli stage market develop
formal unveil focu treat patient year investor meet specif edward
present observ studi patient nation echocardiograph databas
australia neda suggest moder patient similar five-year all-caus mortal rate sever
patient vs respect edward acknowledg limit studi design
believ highlight import investig opportun better understand tavr
help improv outcom moder patient expect detail potenti market trial
might look like time think still three five year see meaning progress
next-gen sapien edward highlight on-going develop next-gen sapien devic first-in-man
implant alreadi complet expect start pivot trial within next month detail
devic light manag note goal enhanc control precis improv safeti efficaci
expect manag provid concret detail updat product time think edward
strong histori innov expect solidifi compani leadership posit
improv diagnostics/pati care support sustain long-term market growth manag remain focus
initi improv patient access tavr treatment proper diagnosi referr improv
hospit roi/effici ensur continu focu develop tavr capabl initi
includ work close hospit provid support step like patient screen case plan
imagin select even inventori manag streamlin post-procedur care altogeth believ
import block tackl effort sustain market develop
encourag compani continu focu help sustain adopt util tavr next
sever year believ underappreci initi investor one potenti
meaning chang market dynam time
tmtt despit anoth year disappoint sale growth tmtt segment manag remain commit
seriou player rapidli grow mitral tricuspid market expect reach billion edward highlight
sever development effort within segment expect four differ tmtt pivot trial run
pascal tricuspid repair pascal degen mitral regurgit mr pascal function mr sapien
mitral replac outsid trial edward continu invest develop cardioband product mitral
annular reduct heavili invest next-gen product design mainstream adopt evoqu valv
design mitral tricuspid replac
overal think edward make appropri invest multipl technolog ensur player long-term
tmtt market said temper expect tmtt growth next month compani
look gain experi segment invest clinic evid requir drive larg scale adopt
end lower estim tmtt sale primarili pascal sale europ million million
fourth quarter full year million million respect fourth quarter
lower estim reflect possibl flat sequenti sale follow recent pascal sheath recal result
two three week time lower full year estim lower end manag guidanc
million million impact tmtt revenu total compani revenu remain small today
segment watch repres larg market growth opportun time said believ compani
still remain double-digit top-lin grower sever year driven tavr franchis
savr despit greater compound-annual-growth-rate tavr sale last five year edward manag grow savr
busi approxim five year ago benefit global leadership posit inspiri
valv believ continu grow busi low singl digit go forward growth expect driven
inspiri valv emerg market access tavr limit lesser degre util select patient
popul develop market manag plan support long-term growth segment focus rel
nich surgic product konect aortic valv conduit sutrafix autom sutur deliveri harpoon mitral repair
repres smaller market face less pressur tavr growth estim approxim growth
bottom end compani guidanc rang continu expect pressur tavr growth look
traction new product rais estim
critic critic care expect grow rang full year compani continu benefit
hemospher advanc monitor platform manag remain focus leverag hemospher platform
creat all-in-on monitor solut increas hospit effici multipl new add-on suit plan next
year clearsight fluid manag connect suit long run edward hope
leverag platform creat smart recoveri platform differenti artifici intellig capabl capabl
improv outcom drive adopt
guidanc look conserv edward re-affirmed guidanc sale high end billion billion
repres underli growth rang adjust ep rang look forward
manag provid full year guidanc billion billion repres underli growth
larg bracket street estim billion billion head event full year
adjust ep expect rang compar street estim
respect prior investor meet
tavr sale expect grow rang slightli higher manag inform
low-double-digit guidanc provid third quarter call compar estim go meet
underli growth expect rest edward busi segment follow savr growth
critic care growth tmtt sale million million compos mostli pascal sale
view guidanc conserv given multipl tailwind tavr segment includ sapien recent expand
indic low-risk patient overwhelmingli posit data present partner trial go low-risk
complet clinic pictur tct structur heart updat tct new econom clinic data keep
product pump on-going launch next-gener sapien ultra potenti addit tailwind
new nation coverag determin ncd publish june current model growth
global tavr sale respect believ edward deliv upsid estim driven
catalysts/tailwind describ
conclus stock thought
continu believ edward sustain market leadership acceler tavr market benefit new
product launch recent expand indic treat low-risk patient think market demand build
low-risk high- intermediate-risk patient well recent survey work support use tavr
patient multipl societi call surgic risk score longer guid choic tavr vs savr
look believ manag set appropri conserv expect tavr growth believ
compani capabl deliv upsid benefit acceler tavr market sustain leadership posit
market share trade time new adjust ep target believ underli market dynam
remain posit support continu double-digit growth market growth edward posit global leader
rate stock outperform
risk thesi includ slower-than-anticip market adopt util tavr treatment largest
driver edward tavr growth today tavr space becom increasingli competit could result
share loss edward move forward even competitor take share could aggress price
product could creat greater anticip price pressur edward growth neg impact top-lin
sale tmtt segment edward still rel earli development effort invest clinic support
product tmtt product achiev posit trial result could limit adopt product would limit
newpreviouschang newpreviouschang millioncrit milliontot billiony/i growth margin margin incom margin lifesci ew summari chang modelfull-year guidancefull-year import disclosur
